Spinal Muscular Atrophy Conference
Home/ Scientific Sessions /Spinal Muscular Atrophy Conference
Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is serious genetic illness that weakens movement muscles. It primarily occurs in infants and young children but it can happen later in life. SMA SMN1 results from a defect in genes, which assists in making the required protein needed to maintain nerve cells healthy. Without it, nerve cells that direct muscles, start dying, resulting in muscles shrink and weaken – a condition referred to as atrophy.
The most frequent and serious form is SMA Type 1, hich starts before 6 months of age. Babies with this type can have floppy muscles and organs, weak muscles and trouble moving or sitting. In severe types, it can cause breathing problems and death during the first year of life. Milder types like type 2 or 3 may appear later and can develop more slowly.
Even though there is still no cure, there is treatment that can be used to control symptoms and enhance the life quality. These are physical therapy, oxygen support and medication. Gene therapy has, in recent years, been created to enhance the advancement of SMN protein and slow down the disease.
Early treatment and diagnosis can significantly enhance the outcome for children with SMA.
Related Sessions
1.Alzheimers and Parkinsons Diseases
2.Neuroimmunology and Neurological Infections
3 – Cognitive Neuroscience and Psychology
4 – Neuroinformatics and Computational Neuroscience
5 – Neurological Disorders
6 – Neurobiology
7 – Molecular Neuroscience
8 – Pediatric Neurology
9 – Clinical Neurology
10 – Translational Neurology
11 – Neurogenetics
12 – Neurodegenerative Diseases
13 – Neuropsychiatry
14 – Neuroscience Research
15 – Neuropharmacology and Novel Drug Development
16 – Neurological Interventions and Surgery
17 – Artificial Intelligence in Neurology and Neurosurgery
18 – Neuro-ophthalmology and Auditory Neurology
19 – Aging and Neurology
20 – Brain Tumors and Neuro-Oncology
21 – Stroke Diagnosis and Management
22 – Epilepsy and Seizure Disorders
23 – Psychiatric and Behavioral Disorders
24 – Neurovascular Disorders
25 – Neurology and Systemic Disorders
26 – Neurodevelopmental Disorders
27 – Cognitive and Memory Disorders
28 – Neuroinflammation and Brain Disorders
29 – Neurological Rehabilitation
31 – Trauma and Neurocritical Care
33 – Cellular and Systems Neuroscience
35 – Advances in Neuroimaging Techniques
37 – Rare and Complex Brain Disorders
30 – Global Challenges and Public Health
32 – Neurotoxicology
34 – Behavioral Neuroscience and Social Neuroscience
36 – Addiction and Mental Health
Scientific Program
Keynote Speaker - Dr. Zhenhuan LIU (Oral Presentation - In-Person)
Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Keynote Speaker - Dr. Magda Tsolaki - Oral Presentation (Virtual)
Emeritus Professor of Neurology, Aristotle Univesrsity of Thessaloniki, Makedonia, Greece, Chair of the Greek Federation of Alzheimer’s Disease
Keynote Speaker - Dr. Tatsuro Mutoh, MD, PhD, FAAN - Oral Presentation (In-Person)
Department of Neurology, Fujita Health University Hospital, Toyoake, Aichi, Japan
Scientific Program
Keynote Speaker - Dr. Zhenhuan LIU (Oral Presentation - In-Person)
Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China
Keynote Speaker - Dr. Magda Tsolaki - Oral Presentation (Virtual)
Emeritus Professor of Neurology, Aristotle Univesrsity of Thessaloniki, Makedonia, Greece, Chair of the Greek Federation of Alzheimer’s Disease
Keynote Speaker - Dr. Tatsuro Mutoh, MD, PhD, FAAN - Oral Presentation (In-Person)
Department of Neurology, Fujita Health University Hospital, Toyoake, Aichi, Japan
Committee Members
Kenneth B Storey
Carleton University, Canada
Kindy Mark
University of South Florida, United
Thomas J Webster
Interstellar Therapeutics, United States
Tags